分期双侧磁共振引导聚焦超声苍白球丘脑束切断术治疗帕金森病运动并发症的安全性与疗效
这项前瞻性多中心单臂研究纳入54例有运动并发症的特发性帕金森病患者,先接受单侧MRgFUS苍白球丘脑束切断术,40例后续行双侧治疗。双侧治疗后3个月MDS-UPDRS part III关期上下肢运动评分中位改善32%(p<0·0001),但55%出现治疗相关不良事件,25%在12个月时仍有持续中度或重度不良事件,主要影响言语、步态和平衡。
要点
- 单侧MRgFUS苍白球丘脑束切断术对帕金森病运动并发症安全有效。
- 双侧治疗运动获益较小,但持续中度或重度不良事件增加。
- 双侧术后言语、步态和平衡并发症与历史双侧消融数据一致。
核心结论
- 单侧MRgFUS苍白球丘脑束切断术对帕金森病运动并发症显示安全性和疗效,但双侧治疗运动获益小且持续中度或重度不良事件增加。
研究设计与样本
- 前瞻性、多中心、单臂研究,在9个研究中心(美国6个、西班牙2个、台湾1个)纳入54例特发性、左旋多巴反应性帕金森病伴运动并发症的成人。
主要发现
- 双侧治疗后3个月上下肢关期运动评分中位从33·0分(IQR 28·0-40·5)降至21·0分(15·0-25·5),中位变化10·5分(5·7-20·0),改善32%(18-52),p<0·0001。
- 单侧治疗后21/54例(39%)发生治疗相关不良事件,1例(2%)在6个月时有持续中度不良事件。
- 双侧治疗后22/40例(55%)发生治疗相关不良事件,10例(25%)在12个月时有持续中度或重度不良事件,主要影响言语、步态和平衡;1例(3%)发生严重持续性构音障碍。
临床怎么用
- 单侧MRgFUS苍白球丘脑束切断术可用于改善帕金森病运动并发症。
- 双侧手术需严格选择患者并充分告知累积风险。
局限性
- 单臂设计,无对照,双侧治疗结局仅基于 modified ITT 人群,且40例中36例完成第二次术后12个月随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Parkinson's disease management is often complicated by motor fluctuations and dyskinesia. Although deep brain stimulation addresses these symptoms, its use is limited by invasiveness, potential device failure, and the need for ongoing maintenance. Magnetic resonance-guided focused ultrasound (MRgFUS) provides incisionless, image-guided ablation as an alternative. However, the benefits and harms of staged, bilateral MRgFUS pallidothalamic tractotomy have not been evaluated systematically in prospective multicentre studies. METHODS: In this prospective, multicentre, single-arm study, adults with idiopathic, levodopa-responsive Parkinson's disease and motor complications (Movement Disorders Society Unified Parkinson's Disease Rating Scale [MDS-UPDRS] part IV item 4.2 or 4.4 score ≥2) were enrolled at nine investigational centres (six in the USA, two in Spain, and one in Taiwan). Participants underwent unilateral MRgFUS pallidothalamic tractotomy to the symptom-dominant side. Contralateral pallidothalamic tractotomy followed a minimum of 6 months later for participants meeting prespecified criteria. The primary efficacy endpoint was percent change from baseline to 3 months after the second procedure in the summed MDS-UPDRS part III off-medication upper and lower extremity (ULE) motor scores. Safety outcomes were incidence, severity, and persistence of treatment-related adverse events in the 12 months after each procedure. Safety and efficacy of unilateral treatment were evaluated in the unilateral intention-to-treat (ITT) and safety populations, defined as all patients receiving one or more sonications during the first procedure. The primary outcome and safety of bilateral treatment were evaluated in the bilateral modified ITT (mITT) and safety populations, which required one or more sonications during the second procedure, a baseline motor assessment, and at least one post-bilateral motor assessment. This trial is registered at ClinicalTrials.gov, NCT04728295 and is active, not recruiting. FINDINGS: Between July 12, 2021, and Nov 1, 2023, 54 patients received unilateral treatment and 40 proceeded to bilateral treatment (63 [67%] were male and 31 [33%] were female) and were included in the primary analysis; 36 completed 12-month follow-up after the second procedure. Median bilateral ULE motor scores decreased from 33·0 points (IQR 28·0-40·5) at baseline to 21·0 points (15·0-25·5) at month 3 post-bilateral treatment, a median within-patient change of 10·5 points (5·7-20·0), representing a 32% (18-52) improvement (p<0·0001). Benefits became apparent within 1 month of the first procedure and lasted through to 12 months after the second procedure. Treatment-related adverse events occurred in 21 (39%) of 54 patients after unilateral treatment; one (2%) had a persistent moderate adverse event at 6 months. After bilateral treatment, 22 (55%) of 40 patients had treatment-related adverse events; ten (25%) had persistent moderate or severe adverse events at 12 months, mainly affecting speech, gait, and balance. One (3%) patient developed severe persistent anarthria. INTERPRETATION: Unilateral MRgFUS pallidothalamic tractotomy demonstrated safety and efficacy for Parkinson's disease motor complications; however, bilateral treatment offered small motor gains while increasing persistent moderate or severe adverse events. Post-bilateral treatment complications in speech, gait, and balance are consistent with historical data for bilateral ablative procedures for movement disorders. Although unilateral MRgFUS pallidothalamic tractotomy was beneficial in our study, bilateral procedures demand rigorous patient selection and counselling regarding cumulative risks. FUNDING: Insightec.
引用
- Dalvi A, Eisenberg HM, Wu P, et al. Safety and efficacy of staged, bilateral magnetic resonance-guided focused ultrasound pallidothalamic tractotomy for motor complications of Parkinson's disease: a prospective, multicentre, single-arm trial. Lancet Neurol. 2026. PMID: 42309086. doi:10.1016/S1474-4422(26)00142-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。